John S. Kovach. M.D. founded Lixte and has been its sole administrative officer. Dr. Kovach has directed leading National Cancer Instituteñdesignated Comprehensive Cancer Centers at Mayo Clinic, Rochester, Minnesota and City of Hope National Medical Center, Los Angeles, California. He has extensive experience in medical oncology, anti-cancer drug pharmacology, and in applied medical research, particularly, the early evaluation of new anti-cancer drugs and the development and management of multi-disciplinary highly productive cancer research teams. Dr. Kovach, in consultation with Lixteís advisors and board, is responsible for the selection and prioritization of the scientific directions and goals of Lixte. Francis Johnson, Ph.D. is a chemical pharmacologist who consults for and collaborates with Lixte Inc., in the systematic development of new anti-cancer substances based on a knowledge of defined biochemical abnormalities in specific types of human cancers. Dr. Johnson is a highly experienced synthetic organic chemist who has broad knowledge of pharmacology. He is the principal inventor on approximately 70 patents many of which deal with pharmacologic agents and his academic research, which includes theoretical studies on stereochemistry, synthetic work on many natural products and extensive work on DNA damage, has been reported in more than 170 peer-reviewed publications. Dr. Johnson is also the president of Chem-Master International Inc., a small company founded in 1994, that specializes both in the custom synthesis of chemical intermediates and in the development of new drug substances. Dr. Johnson spent the early part of his career working in the Eastern Research Laboratory, a research institute near Boston, run by the Dow Chemical Co. Since 1974 he has occupied Professorships in both Chemistry and in Pharmacological Sciences at Stony Brook University. Gil N. Schwartzberg, Esq. is a consultant for corporate development. Mr. Schwartzberg is a successful lawyer, entrepreneur, scientific organizational leader, and administrator. He was a principal in the development of two New York Stock Exchange corporations, L.A. Gear, Inc. and Sketchers USA, Inc. Mr. Schwartzberg also led, first, as chairman of the Board and then as President and CEO, the development of the City of Hope National Medical Center, Los Angeles, CA. into one of the nationís premier National Cancer Institute-designated Comprehensive Cancer Centers. His leadership and perceptive insights into the complexities of integrating basic scientific research with state-of-the-art, life-saving, compassionate cancer care and the creation of a new graduate school in the biosciences at the City of Hope were recognized by that institution in 2003 by awarding Mr. Schwartzberg a Doctor of Science degree.